CS MEDICA has just received the first order for the Israeli market from their partner Forbe HealthCare Ltd.  The order includes all CS MEDICA's medical CBD products, CANNASEN® CBD Arthritis-, Psoriasis-, Protective Nasal-  and Wound gel, Pain Patch and Nasal Spray Night, with a total amount of units of 65.000 and an order value of DKK 2.6 million.  This order is the first of the total minimum order amoounting to DKK 37,1 million, covering the next 3,5 years.

According to the Israeli legislation on CBD, nutraceuticals and cosmetics containing CBD are illegal for the time being, the next 2 years, while medical technical CBD products are excluded in this prohibition. With CS MEDICA's less than 1PPB THC certificates showing zero traces of THC, the CANNASEN® CBD medical CBD product line are in process to legally be registered and sold in Israel. The launch of CS MEDICA's medical technical products with CBD will be the first legal CBD products to be launched on the Israeli market.

Lone Henriksen, CEO CS MEDICA comments
"We are very proud to be able to become the first legal CBD brand to enter the Israeli market, notably as Israel is one of the global leaders within the area of CBD and Cannabis research.  We look very much forward to our collaboration with our strong partner in Israel, Forbe HealthCare Ltd., and we are confident that we together will develop a strong success story in the Israeli market."